Clinical trial
Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe…
NCT00032747 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00032747 |
|---|---|
| Title | Safety Study of Vasopressin V2 Receptor Antagonist on Patients With Severe Chronic Heart Failure (AQUAVIT). |
| Official title | A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Effects of Vasopressin V2 Receptor Antagonist on Clinical Improvement in Patients With Severe Chronic Heart Failure |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Heart Failure |
| Intervention type | Drug |
| Interventions | Vasopressin V2 Receptor Antagonist |
| Enrollment | 338 |
| Start date | Aug 1, 2001 |
| Completion | Feb 1, 2003 |
| First posted | Apr 1, 2002 |
| Last update posted | Jun 17, 2008 |
| Countries | Canada, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: